Version 1
: Received: 26 July 2024 / Approved: 28 July 2024 / Online: 30 July 2024 (09:18:17 CEST)
Version 2
: Received: 18 September 2024 / Approved: 19 September 2024 / Online: 19 September 2024 (11:47:05 CEST)
Version 3
: Received: 23 September 2024 / Approved: 24 September 2024 / Online: 24 September 2024 (12:30:08 CEST)
How to cite:
Justiz-Vaillant, A.; Gopaul, D.; Asin-Milan, O.; Arrozarena-Fundora, R.; Thompson, R.; Soodeen, S.; Akpaka, P. E.; Unakal, C. Challenges and Advances in Cervical Cancer Prevention for HIV-Positive Individuals. Preprints2024, 2024072238. https://doi.org/10.20944/preprints202407.2238.v3
Justiz-Vaillant, A.; Gopaul, D.; Asin-Milan, O.; Arrozarena-Fundora, R.; Thompson, R.; Soodeen, S.; Akpaka, P. E.; Unakal, C. Challenges and Advances in Cervical Cancer Prevention for HIV-Positive Individuals. Preprints 2024, 2024072238. https://doi.org/10.20944/preprints202407.2238.v3
Justiz-Vaillant, A.; Gopaul, D.; Asin-Milan, O.; Arrozarena-Fundora, R.; Thompson, R.; Soodeen, S.; Akpaka, P. E.; Unakal, C. Challenges and Advances in Cervical Cancer Prevention for HIV-Positive Individuals. Preprints2024, 2024072238. https://doi.org/10.20944/preprints202407.2238.v3
APA Style
Justiz-Vaillant, A., Gopaul, D., Asin-Milan, O., Arrozarena-Fundora, R., Thompson, R., Soodeen, S., Akpaka, P. E., & Unakal, C. (2024). Challenges and Advances in Cervical Cancer Prevention for HIV-Positive Individuals. Preprints. https://doi.org/10.20944/preprints202407.2238.v3
Chicago/Turabian Style
Justiz-Vaillant, A., Patrick Eberechi Akpaka and Chandrashekhar Unakal. 2024 "Challenges and Advances in Cervical Cancer Prevention for HIV-Positive Individuals" Preprints. https://doi.org/10.20944/preprints202407.2238.v3
Abstract
Human papillomavirus (HPV) is a well-known cause of cervical cancer, with HIV infection exacerbating the prevalence of high-risk HPV (HR-HPV) and cervical intraepithelial neoplasia (CIN). ART has been shown to reduce the likelihood of developing squamous intraepithelial lesions (SILs) and HR-HPV prevalence, although its impact on invasive cervical cancer remains inconclusive. In a study in Accra, 250 sexually active HIV-positive women exhibited a high HPV prevalence, emphasising the need for regular screening. HPV testing, visual inspection with acetic acid (VIA), and cytology-based tests are primary screening methods, each with specific advantages and limitations. Cervical cancer rates in sub-Saharan Africa are alarmingly high, necessitating targeted vaccination and prevention strategies.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.